Emerging Markets Earnings Roundup: AstraZeneca (Part 6)
This article was originally published in PharmAsia News
Continuing double-digit growth in China, AstraZeneca reports strong performance for its Pulmicort, amid rival GSK’s 56% decline for its bestselling Advair/Seretide. Does GSK’s pain mean AstraZeneca’s gain?
You may also be interested in...
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.